This study will create a comprehensive, multicomponent behavioral intervention package (ONBOARD; OvercomiNg Barriers \& Obstacles to Adopting Diabetes Devices). ONBOARD will provide adults with type 1 diabetes (T1D) the skills to maximize benefit and minimize daily interference from barriers associated with continuous glucose monitoring (CGM) and increase readiness for closed loop.
The proposed research will create and refine the ONBOARD intervention for CGM use. Participants will be tracked using metrics of A1c, time in glucose target range, number of days using CGM, blood glucose (BG) downloads, diabetes problem solving, diabetes distress, and technology attitudes. The investigators will examine whether ONBOARD leads to improved diabetes and psychosocial outcomes and sustained CGM use. At the end of this study, the investigators will have created and refined a comprehensive, multicomponent intervention package to promote increased and sustained uptake of CGM and increase readiness for closed loop adoption.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
Stanford University
Stanford, California, United States
Hemoglobin A1c (HbA1c)
Glycated haemoglobin (HbA1c)
Time frame: baseline, month 3
Number of Participants Who Withdraw or Are Lost to Followup Over the Course of the Study
The number of participants who withdraw or are lost to followup over the course of the study is used as a measure of attrition
Time frame: Duration of study participation (up to three months)
Number of Eligible Individuals Who Agree to Participate in the Study
Number of eligible individuals who agree to participate in the study out of all those approached during recruitment
Time frame: During screening visit (up to 50 minutes)
Satisfaction With Intervention Survey
Participant-rated Satisfaction Survey: Individual question scores are presented, each was measured on a Likert scale (0-4), higher scores mean more satisfaction.
Time frame: Month 3
Percentage of Time in Range of Continuous Glucose Monitor Values Between 70 and 180 mg/dL
Baseline and 3-month followup continuous glucose monitor values for percent time spent between 70-180mg/dl
Time frame: two weeks prior to starting intervention and two weeks after the intervention (average approximately 3 months)
Diabetes Distress Scale for Type 1 Diabetes
Unabbreviated Scale Title: Diabetes Distress Scale for Type 1 Diabetes (T1-DDS) is a 28-item self-report scale that highlights seven critical dimensions of distress: powerlessness, management distress, hypoglycemia distress, negative social perceptions, eating distress, physician distress, and friends/family distress. A total score is calculated using the mean of all item scores. Subscale scores are calculated using the means of specific items for each subscale. Min Value: 1 Max Value: 6 Higher scores mean worse outcome/more distress
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: baseline, month 3
Glucose Monitoring System Satisfaction Survey (GMSS-T1D)
Scale title "Glucose Monitoring System Satisfaction Survey - Type 1 Diabetes" Min:1 Max:5 Higher mean scores mean worse outcome
Time frame: baseline, month 3
Percentage of CGM Data Downloaded and Available for Analysis
Baseline and 3-month follow-up percentage of continuous glucose monitoring values using data available from device for use in analyses.
Time frame: two weeks prior to starting intervention and two weeks after the intervention (average approximately 3 months)
Mean Glucose Level
Mean glucose level from continuous glucose monitoring data at baseline and month 3
Time frame: baseline, month 3
Barriers to Diabetes Device Use Survey
Title: Barriers to Diabetes Device Use is a 19-item list of barriers to diabetes device use. Participants can select between 0 and 19 barriers. Examples of barriers are: cost, insurance, lack of family support, lack of support from the diabetes care team, and not liking devices on the body. Min: 0 Max: 19 higher scores mean a worse outcome
Time frame: baseline, month 3
Diabetes Technology Attitudes Survey
Title: Diabetes Technology Attitudes Survey, a 6-item survey that asks about general attitudes about the role diabetes technology in one's life and the extent to which someone finds technology helpful for managing diabetes. Min: 1 Max: 5 Mean Score, higher score means better outcome
Time frame: Baseline, Month 3
Fear of Hypoglycemia - Worry Survey
Scale Title: Hypoglycemia Fear Survey II - Worry Subscale is an 18-item subscale that presents a list of concerns people with diabetes sometimes have about low blood sugar. Respondents answer based on their level of worry about each item for the past 6 months. A total score is calculated by summing individual item scores. Min: 0 Max: 4 Higher score indicates worse outcome
Time frame: baseline, month 3
Hypoglycemia Confidence Scale
Title: Hypoglycemia Confidence Scale is a 9-item scale that asks about how confident the respondent is in managing problems with hypoglycemia in a range of situations. A total score is calculated using the mean of all item scores. Min: 1 Max: 4 Higher score means better outcome/more confidence
Time frame: baseline, month 3
Technology Use For Diabetes Problem Solving Scale
Scale: Technology Use For Diabetes Problem Solving Scale is a 9-item scale that asks participants to rate how often they use different types of technology (eg phone, websites, looking at graphs of their glucose data) in managing their diabetes, solving problems and finding answers to questions that arise in managing diabetes. A total score is calculated by summing all items. Min: 0 Max: 5 Higher score means a better outcome
Time frame: baseline, month 3
INSPIRE Survey
Title: INsulin Dosing Systems: Perceptions, Ideas, Reflections, and Expectations (INSPIRE) is a 31-item survey that assesses perceived benefits and burdens of automated insulin delivery systems. A total score is calculated by obtaining a mean score across items, then multiplying the mean score by 25 to scale total INSPIRE measure scores from 0 to 100. Min: 1 Max: 5 High score means more positive outcome
Time frame: baseline, month 3
Frequency of Blood Glucose Monitoring
Frequency will be measured as the number of times a day the participant checks blood glucose level using glucose meter
Time frame: 3 months